Literature DB >> 26913938

Response Rate as an Approval End Point in Oncology: Back to the Future.

Gideon M Blumenthal1, Richard Pazdur1.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 26913938     DOI： 10.1001/jamaoncol.2015.6352

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  8 in total

1.  A Primer on RECIST 1.1 for Oncologic Imaging in Clinical Drug Trials.

Authors:  Kathleen Ruchalski; Marta Braschi-Amirfarzan; Michael Douek; Victor Sai; Antonio Gutierrez; Rohit Dewan; Jonathan Goldin
Journal:  Radiol Imaging Cancer       Date:  2021-05

2.  Approvals in 2016: the march of the checkpoint inhibitors.

Authors:  Gideon M Blumenthal; Richard Pazdur
Journal:  Nat Rev Clin Oncol       Date:  2017-02-20       Impact factor: 66.675

3.  Analysis of Response Data for Assessing Treatment Effects in Comparative Clinical Studies.

Authors:  Bo Huang; Lu Tian; Zachary R McCaw; Xiaodong Luo; Enayet Talukder; Mace Rothenberg; Wanling Xie; Toni K Choueiri; Dae Hyun Kim; Lee-Jen Wei
Journal:  Ann Intern Med       Date:  2020-07-07       Impact factor: 25.391

4.  Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA-Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis.

Authors:  Seung Tae Kim; Kimberly C Banks; Se-Hoon Lee; Kyung Kim; Joon Oh Park; Se Hoon Park; Young Suk Park; Ho Yeong Lim; Won Ki Kang; Richard B Lanman; AmirAli Talasaz; Keunchil Park; Jeeyun Lee
Journal:  JCO Precis Oncol       Date:  2017-06-26

5.  Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer.

Authors:  Dickran Kazandjian; Gideon M Blumenthal; Lola Luo; Kun He; Ingrid Fran; Steven Lemery; Richard Pazdur
Journal:  Oncologist       Date:  2016-06-21

6.  Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies.

Authors:  Gideon M Blumenthal; Paul G Kluetz; Julie Schneider; Kirsten B Goldberg; Amy E McKee; Richard Pazdur
Journal:  Oncologist       Date:  2017-06-02

7.  Tumor Size and Overall Survival in Patients With Platinum-Resistant Ovarian Cancer Treated With Chemotherapy and Bevacizumab.

Authors:  Alexandre Sostelly; François Mercier
Journal:  Clin Med Insights Oncol       Date:  2019-05-28

Review 8.  Novel Nuclear Medicine Imaging Applications in Immuno-Oncology.

Authors:  Stefano Frega; Alessandro Dal Maso; Giulia Pasello; Lea Cuppari; Laura Bonanno; PierFranco Conte; Laura Evangelista
Journal:  Cancers (Basel)       Date:  2020-05-21       Impact factor: 6.639
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.